查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1882972

治療性神經毒素市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2024-2032）

Therapeutic Neurotoxin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 309 Pages | 商品交期: 請詢問到貨日

價格

治療性神經毒素市場成長因素

受神經系統疾病盛行率上升以及肉毒桿菌療法在各醫療專科的快速普及推動，全球治療性神經毒素市場正穩步擴張。根據本報告預測，該市場規模預計將在2024年達到58.6億美元，並在2025年增長至63.4億美元。預計到2032年，該市場規模將達到112.2億美元，預測期內複合年增長率（CAGR）為8.5%。 2024年，北美地區佔了72.6%的市場佔有率，這主要得益於其先進的醫療保健體係以及對治療性神經毒素在各種適應症中的早期應用。

治療性神經毒素（主要是A型和B型肉毒桿菌毒素）廣泛用於治療慢性偏頭痛、頸肌張力失調、眼瞼痙攣、痙攣和膀胱過動症等神經系統疾病。其作用機轉為阻斷神經肌肉傳遞，進而減輕肌肉過度活動及相關症狀。艾伯維、益普生製藥、默茲製藥和瑞凡斯製藥等主要公司不斷獲得監管部門批准，並持續創新以拓展適應症，這些都持續推動全球市場成長。

市場動態

成長因素

關鍵成長驅動因素是全球神經系統疾病負擔的日益加重。根據世界衛生組織的數據（2024年3月），到2021年，頭痛疾病將影響全球約40%的人口（約31億人）。慢性偏頭痛是全球主要的致殘原因之一，因此對有效的神經毒素療法的需求日益增長。肉毒桿菌毒素可顯著降低偏頭痛發作的頻率和嚴重程度，使其成為傳統療法無效的患者的重要選擇。

限制

高昂的治療費用和低收入國家有限的保險覆蓋範圍阻礙了市場准入。例如，根據2023年發表在 "Cureus" 雜誌上的一項研究，肉毒桿菌治療偏頭痛的年費用約為3000美元，這對許多患者來說過於昂貴。此外，諸如眼瞼下垂、肌肉無力和頸部疼痛等副作用會影響患者的依從性，並影響治療選擇。

機會

越來越多的研究探討了神經毒素在精神醫學中的應用，展現出巨大的潛力。研究表明，A型肉毒桿菌毒素（BoNT/A）可能透過杏仁核調節情緒處理，從而在重度憂鬱症（MDD）、創傷後壓力症候群（PTSD）和社交焦慮症等疾病中具有潛在的治療價值。 2024年3月，Healis Therapeutics與麻省總醫院合作，啟動了CKDB-501A（一種A型肉毒桿菌毒素（BoNT/A）神經調節劑）治療多種神經精神疾病的臨床試驗。

挑戰

生物相似藥的興起加劇了價格競爭，構成了一項重大挑戰。 2024年9月，永旺生物製藥（AEON BioPharma）透過FDA的351(k)途徑推進了ABP-450的研發，這是一種旨在達到肉毒桿菌毒素等效性的生物類似藥。隨著生物相似藥進入市場，品牌神經毒素生產商面臨價格壓力，並轉向更具成本效益的替代方案。

市場趨勢

一個新興的關鍵趨勢是開發無針神經毒素輸送系統。許多患者反映注射治療會引起焦慮和不適，尤其是在原發性腋窩多汗症等疾病。 Dermata Therapeutics和Revance等公司正在評估局部神經毒素製劑作為替代方案。 2025年1月，這兩家公司合作探索將Xyngari（局部海綿粉）和Daxxify組合用於局部神經毒素輸送。

市場區隔亮點

按類型

2024年，A型肉毒桿菌毒素憑藉其大量核准的治療產品佔市場主導地位。近期獲準的產品，例如Merz Pharma的Xeomin（於2023年在澳洲獲準），進一步鞏固了該細分市場的領先地位。

B型肉毒桿菌毒素雖然市佔率較小，但透過持續的臨床試驗不斷擴大其市場佔有率。

按應用

由於肌肉痙攣發病率的上升以及痙攣治療適應症的擴大，痙攣治療佔了最大的市場佔有率。慢性偏頭痛則因全球需求的成長而成為第二大細分市場。

按最終使用者

2024年，由於病患數量增加、報銷制度的完善以及治療能力的提升，醫院將佔市場主導地位。由於對神經系統疾病和治療護理的巨大需求，專科診所也隨之發展。

區域展望

2024年，北美市場規模達到42.4億美元，憑藉較高的患者認知度、強有力的報銷政策和積極的臨床試驗，保持著其市場主導地位。由於持續的產品審批和治療的廣泛應用，美國仍然是最大的國內市場。

歐洲佔第二大市場佔有率，這主要得益於神經系統疾病盛行率的上升以及產品審批的增加，例如益普生公司Dysport於2022年獲批的延期上市。

由於疾病盛行率的上升和持續的研發投入，亞太地區預計將實現最快成長。

拉丁美洲和中東/非洲地區在神經毒素療法普及的推動下，將持續保持穩定成長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家治療量概覽
  • 主要國家監理狀況概覽
  • 主要國家報銷狀況概覽
  • 主要公司新產品發布
  • 主要公司在研產品線分析

第五章：全球治療性神經毒素市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 按類型劃分
    • A型肉毒桿菌毒素
    • B型肉毒桿菌
  • 市場分析、洞察與預測 - 按應用劃分
    • 額紋
    • 眉間紋
    • 魚尾紋
    • 其他
  • 市場分析、洞察與預測 - 按最終用戶劃分
    • 專科診所及皮膚科診所
    • 醫院和診所
    • 其他
  • 市場分析、洞察與預測 - 按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美治療性神經毒素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲治療性神經毒素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 烏克蘭
    • 歐洲其他地區

第八章 亞太地區治療性神經毒素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 泰國
    • 台灣
    • 亞太其他地區

第九章：拉丁美洲治療性神經毒素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 智利
    • 哥倫比亞
    • 拉丁美洲其他地區

第十章：中東和非洲治療性神經毒素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 埃及
    • 伊朗
    • 土耳其
    • 黎巴嫩
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • 艾伯維公司（Allergen Therapeutics）
    • 益普生製藥
    • 默茲製藥
    • HUGEL公司
    • Evolus公司
    • 高德美
    • 瑞凡斯
    • Supernus製藥
    • 上海復星醫藥（集團）有限公司
    • 大王製藥股份有限公司
Product Code: FBI113754

Growth Factors of therapeutic neurotoxin Market

The global therapeutic neurotoxin market is expanding steadily, driven by the rising prevalence of neurological disorders and rapidly growing adoption of botulinum toxin therapies across medical specialties. According to the report, the market size reached USD 5.86 billion in 2024, is projected to rise to USD 6.34 billion in 2025, and is expected to reach USD 11.22 billion by 2032, reflecting a CAGR of 8.5% during the forecast period. In 2024, North America held a dominant 72.6% share of the market owing to advanced healthcare systems and early adoption of therapeutic neurotoxins across various indications.

Therapeutic neurotoxins-primarily botulinum toxin types A and B-are widely used to manage neurological conditions such as chronic migraines, cervical dystonia, blepharospasm, spasticity, and overactive bladder. Their mechanism involves blocking neuromuscular transmission, thereby reducing muscle overactivity and associated symptoms. Increasing regulatory approvals for expanded uses and continuous innovation by key companies such as AbbVie Inc., Ipsen Pharma, Merz Pharma, and Revance Therapeutics continue to support global market growth.

Market Dynamics

Drivers

The primary growth driver is the increasing global burden of neurological disorders. WHO data (March 2024) reported that headache disorders affected approximately 40% of the global population, representing nearly 3.10 billion individuals in 2021. Chronic migraine is one of the leading causes of disability worldwide, thereby increasing the demand for effective neurotoxin-based therapies. Botulinum toxin significantly reduces migraine frequency and severity, making it a critical option for patients who do not respond to conventional therapies.

Restraints

High treatment costs and limited reimbursement in low-income countries restrict market accessibility. For example, a 2023 study published in Cureus found that Botox therapy for migraines costs around USD 3,000 per year, making it unaffordable for many patients. Additionally, side effects such as eyelid ptosis, muscle weakness, and neck pain impact patient adherence and influence treatment preferences.

Opportunities

Growing research exploring neurotoxin use in psychiatry presents substantial opportunities. Studies indicate that Botulinum toxin type A (BoNT/A) may modulate emotional processing through the amygdala, creating potential therapeutic value in conditions such as major depressive disorder (MDD), PTSD, and social anxiety disorder. In March 2024, Healis Therapeutics partnered with Massachusetts General Hospital to begin clinical trials for CKDB-501A, a BoNT/A neuromodulator for multiple neuropsychiatric conditions.

Challenges

The rise of biosimilars poses a strong challenge by increasing price competition. In September 2024, AEON Biopharma advanced its ABP-450 biosimilar through the FDA's 351(k) pathway, targeting equivalence to BOTOX. As biosimilars enter the market, branded neurotoxin manufacturers face pricing pressure and a shift toward more cost-effective alternatives.

Market Trends

A major emerging trend is the development of needle-free neurotoxin delivery systems. Many patients experience anxiety and discomfort with injectable treatments, particularly for conditions such as primary axillary hyperhidrosis. Companies like Dermata Therapeutics and Revance are evaluating topical neurotoxin applications as an alternative. In January 2025, both companies collaborated to explore a combination of Xyngari (topical Spongilla powder) with Daxxify for topical neurotoxin delivery.

Segmentation Highlights

By Type

Botulinum toxin type A dominated the market in 2024 due to a large number of approved therapeutic products. Recent approvals, such as Merz Pharma's 2023 approval for Xeomin in Australia, contribute to segment leadership.

Botulinum toxin type B holds a smaller share but continues expanding via ongoing clinical trials.

By Application

The spasticity segment held the largest share owing to the rising incidence of muscular spasticity and increasing label expansions for spasticity treatment. Chronic migraine represented the second-largest segment due to extensive global demand.

By End User

Hospitals dominated the market in 2024 due to higher patient inflow, improved reimbursement, and advanced treatment capabilities. Specialty clinics followed with significant demand for targeted neurological and therapeutic care.

Regional Outlook

In 2024, North America generated USD 4.24 billion, maintaining its dominance through high patient awareness, strong reimbursement policies, and active clinical trials. The U.S. remains the largest national market with continuous product approvals and broad therapeutic adoption.

Europe holds the second-largest share, driven by rising neurological disease prevalence and product approvals such as Ipsen's Dysport label expansion in 2022.

Asia Pacific is projected to grow fastest due to increasing disease prevalence and ongoing R&D investments.

Latin America and the Middle East & Africa continue to expand steadily, supported by increasing access to neurotoxin therapies.

Conclusion

Growing from USD 5.86 billion in 2024 to USD 11.22 billion by 2032, the therapeutic neurotoxin market is poised for strong long-term growth fueled by increasing neurological disease burdens, expanding clinical applications, and continuous innovation from key industry players.

Segmentation By Type

  • Botulinum Toxin Type A
  • Botulinum Toxin Type B

By Application

  • Chronic Migraine
  • Spasticity
  • Overactive Bladder
  • Cervical Dystonia
  • Blepharospasm
  • Others

By End-user

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America (By Type, Application, End-user, and Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Type, Application, End-user, and Country/Sub-Region)
    • U.K. (By Application)
    • Germany (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Scandinavia (By Application)
    • Ukraine (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Type, Application, End-user, and Country/Sub-Region)
    • Japan (By Application)
    • China (By Application)
    • India (By Application)
    • Australia (By Application)
    • South Korea (By Application)
    • Thailand (By Application)
    • Taiwan (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Type, Application, End-user, and Country/Sub-Region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Colombia (By Application)
    • Argentina (By Application)
    • Venezuela (By Application)
    • Chile (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Type, Application, End-user, and Country/Sub-Region)
    • UAE (By Application)
    • Saudi Arabia (By Application)
    • Turkey (By Application)
    • Egypt (By Application)
    • Lebanon (By Application)
    • Iran (By Application)
    • Rest of GCC (By Application)
    • South Africa (By Application)
    • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of the Number of Therapeutic Procedures, By Key Countries
  • 4.2. Overview of Regulatory Scenario, By Key Countries
  • 4.3. Overview of Reimbursement Scenario, By Key Countries
  • 4.4. New Product Launches, By Key Players
  • 4.5. Pipeline Analysis, By Key Players

5. Global Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Botulinum Toxin Type A
    • 5.1.2. Botulinum Toxin Type B
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Forehead Wrinkles
    • 5.2.2. Glabellar Lines
    • 5.2.3. Crow's Feet
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-User
    • 5.3.1. Specialty & Dermatology Clinics
    • 5.3.2. Hospitals & Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Botulinum Toxin Type A
    • 6.1.2. Botulinum Toxin Type B
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Forehead Wrinkles
    • 6.2.2. Glabellar Lines
    • 6.2.3. Crow's Feet
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-User
    • 6.3.1. Specialty & Dermatology Clinics
    • 6.3.2. Hospitals & Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Botulinum Toxin Type A
    • 7.1.2. Botulinum Toxin Type B
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Forehead Wrinkles
    • 7.2.2. Glabellar Lines
    • 7.2.3. Crow's Feet
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-User
    • 7.3.1. Specialty & Dermatology Clinics
    • 7.3.2. Hospitals & Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Ukraine
    • 7.4.8. Rest of Europe

8. Asia Pacific Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Botulinum Toxin Type A
    • 8.1.2. Botulinum Toxin Type B
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Forehead Wrinkles
    • 8.2.2. Glabellar Lines
    • 8.2.3. Crow's Feet
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-User
    • 8.3.1. Specialty & Dermatology Clinics
    • 8.3.2. Hospitals & Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. South Korea
    • 8.4.6. Thailand
    • 8.4.7. Taiwan
    • 8.4.8. Rest of Asia Pacific

9. Latin America Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Botulinum Toxin Type A
    • 9.1.2. Botulinum Toxin Type B
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Forehead Wrinkles
    • 9.2.2. Glabellar Lines
    • 9.2.3. Crow's Feet
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-User
    • 9.3.1. Specialty & Dermatology Clinics
    • 9.3.2. Hospitals & Clinics
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Chile
    • 9.4.4. Colombia
    • 9.4.5. Rest of Latin America

10. Middle East & Africa Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Botulinum Toxin Type A
    • 10.1.2. Botulinum Toxin Type B
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Forehead Wrinkles
    • 10.2.2. Glabellar Lines
    • 10.2.3. Crow's Feet
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By End-User
    • 10.3.1. Specialty & Dermatology Clinics
    • 10.3.2. Hospitals & Clinics
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. Egypt
    • 10.4.2. Iran
    • 10.4.3. Turkey
    • 10.4.4. Lebanon
    • 10.4.5. UAE
    • 10.4.6. Saudi Arabia
    • 10.4.7. South Africa
    • 10.4.8. Rest of Middle East and Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. AbbVie Inc. (Allergen Therapeutics)
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Ipsen Pharma
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merz Pharma
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. HUGEL, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Evolus, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. GALDERMA
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. REVANCE
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Supernus Pharmaceuticals, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. DAEWOONG PHARMACEUTICAL CO., LTD
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 3: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 4: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 6: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 7: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 8: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country, 2019-2032
  • Table 9: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 10: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 11: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 12: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 14: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 15: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 16: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 17: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 18: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 19: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 20: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 22: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 23: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 24: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Therapeutic Neurotoxin Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Therapeutic Neurotoxin Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global Therapeutic Neurotoxin Market Value Share (%), by Application, 2024 & 2032
  • Figure 4: Global Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024 & 2032
  • Figure 5: Global Therapeutic Neurotoxin Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Therapeutic Neurotoxin Market Value (USD billion), by Type, 2024 & 2032
  • Figure 7: North America Therapeutic Neurotoxin Market Value Share (%), by Type, 2024
  • Figure 8: North America Therapeutic Neurotoxin Market Value (USD billion), by Application, 2024 & 2032
  • Figure 9: North America Therapeutic Neurotoxin Market Value Share (%), by Application, 2024
  • Figure 10: North America Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 11: North America Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024
  • Figure 12: North America Therapeutic Neurotoxin Market Value (USD billion), by Country, 2024 & 2032
  • Figure 13: North America Therapeutic Neurotoxin Market Value Share (%), by Country, 2024
  • Figure 14: Europe Therapeutic Neurotoxin Market Value (USD billion), by Type, 2024 & 2032
  • Figure 15: Europe Therapeutic Neurotoxin Market Value Share (%), by Type, 2024
  • Figure 16: Europe Therapeutic Neurotoxin Market Value (USD billion), by Application, 2024 & 2032
  • Figure 17: Europe Therapeutic Neurotoxin Market Value Share (%), by Application, 2024
  • Figure 18: Europe Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 19: Europe Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024
  • Figure 20: Europe Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by Type, 2024 & 2032
  • Figure 23: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by Type, 2024
  • Figure 24: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by Application, 2024 & 2032
  • Figure 25: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by Application, 2024
  • Figure 26: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 27: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024
  • Figure 28: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2024
  • Figure 30: Latin America Therapeutic Neurotoxin Market Value (USD billion), by Type, 2024 & 2032
  • Figure 31: Latin America Therapeutic Neurotoxin Market Value Share (%), by Type, 2024
  • Figure 32: Latin America Therapeutic Neurotoxin Market Value (USD billion), by Application, 2024 & 2032
  • Figure 33: Latin America Therapeutic Neurotoxin Market Value Share (%), by Application, 2024
  • Figure 34: Latin America Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 35: Latin America Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024
  • Figure 36: Latin America Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by Type, 2024 & 2032
  • Figure 39: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by Type, 2024
  • Figure 40: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by Application, 2024 & 2032
  • Figure 41: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by Application, 2024
  • Figure 42: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 43: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024
  • Figure 44: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2024
  • Figure 46: Global Therapeutic Neurotoxin Market Share (%), by Company, 2024